Introduction

Treadwell is a science-first organisation leveraging deep mechanistic insights and cutting-edge tools to uncover novel targets and to translate those insights into clinical candidates. With a robust set of internal discovery tools and capabilities at the Toronto-based R&D hub, Treadwell is intently focused on translating innovative scientific ideas and therapeutic targets into practice-changing medicines.

Focus areas

The company is developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company’s robust, internally developed clinical stage pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a best-in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1. Treadwell also has a robust pre-clinical pipeline with multiple biologic and next generation TCR based autologous cell therapy programs.